Who we are

MorphoSys's proprietary HuCAL antibody library is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets.

 

video message

A short introduction to MorphoSys`s business by Dr. Simon Moroney.
More …

 

Career

MorphoSys provides an attractive international working environment.
More …

 

News

  • 02/09/2010 // MorphoSys Initiates Program Against Drug-Resistant MRSA Infections

    more …

  • 01/09/2010 // MorphoSys to Present at Three Investor Conferences in September

    more …

Find more releases in the news overview

Product Pipeline

MorphoSys’s portfolio comprises more than 70 antibody development programs. More …

 

Press & Investors

MorphoSys is listed on the Frankfurt Stock Exchange and a TecDAX member. More …